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Abstract
Since 1942, therapy with radioiodine (RIT) has gained a major role
in the treatment of benign thyroid disorders, notably hyperthyroid-
ism caused by Graves’ disease or toxic multinodular goitre (thy-
roid autonomy). In iodine deficient areas thyroid autonomy ac-
counts for 40–50% of all cases with hyperthyroidism. RIT has be-
come a cost-effective first-line procedure in autonomy-patients with
latent or overt hyperthyroidism, especially in the absence of a large
goitre, after thyroid surgery and in elderly patients with associated
conditions who carry a high intra- or perioperative risk.
Decisions concerning the definitive treatment of thyroid autono-
my should take into account previous episodes of hyperthyroid-
ism, objective parameters of risk stratification in euthyroid patients
as well as concomitant diseases and the probability of iodine ex-
posure in the future. In Central Europe the majority of investiga-
tors prefer to estimate the therapeutic activity individually by a ra-
dioiodine test. TCTUs (global 99m-Tc-pertechnetate thyroid up-
take under suppression) — based dose concepts have been prov-
en to be highly effective in the elimination of autonomy and carry
a low (< 10%) risk of postradioiodtherapeutic hypothyroidism.
Radioiodine therapy for autonomy has been found to be both
effective and safe and without major early or late side effects.
The most frequent complication is hypothyroidism requiring life-
long follow-up.
Key words: Thyroid autonomy, TCTUs, I-131, toxic
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Introduction
Thyroid autonomy (Plummer’s disease) can be differentiated
in focal (unifocal and multifocal) or diffuse (disseminated) TSH-
-independent hyperfunction of the thyroid.
From a descriptive point of view, functional autonomy is cha-
racterised by the proliferation of thyroid follicular cells with increased
iodine metabolism and by a high degree of independence from
the regulatory interference by the hypothalamic-hypophyseal feed-
back mechanism. In iodine deficiency areas nodular goitres and,
as a consequence, hyperfunctioning thyroid nodules (autonomies)
are highly prevalent. In these areas thyroidal autonomy is four
to fivefold more frequent than in areas with a sufficient iodine
supply for the population [1]. Moreover iodine supplementa-
tion leads to a significant reduction in thyroid autonomy [2].
The prevalence and functional relevance of autonomy increas-
es with age, goitre volume and goitre nodularity [3]. In nodu-
lar goitres above 50 g a prevalence of greater than 70% can
be expected [4].
Functional thyroidal autonomy is a gradual process. As the vol-
ume of autonomous tissue increases with time, suppression of TSH
and the remaining thyroid will take place and subsequently sponta-
neous or iodine-induced thyrotoxicosis may occur. The incidence
of hyperthyroidism mainly depends on the quantity of autonomous
tissue and the amount and duration of iodine supply [5].
Constitutively activating thyrotropin receptor mutations and
mutations of the GSa protein have recently been identified as the
most frequent molecular factors in the pathogenesis of unilocular
and multilocular toxic thyroid nodules in iodine deficient areas [6–
–8]. As a consequence of these changes, chronic activation of
the adenylate-cyclase-cAMP-cascade takes place, followed by
overexpression of the sodium iodine symporter (NIS), thyroglobu-
lin synthesis, iodine oxidation and thyroid hormone synthesis and
release. Development of autonomous nodules is a non-reversible
process and therefore definitive treatment will be necessary in
spontaneous and iodine-induced hyperthyroid patients and in
those who carry a high risk of hyperthyroidism.
This overview summarises the diagnosis of thyroid autonomy
and describes current concepts for an individual dose estimation
in autonomy patients. In addition the results of different therapy-
-regimens and early and late side effects of I-131 treatment will be
discussed.
Diagnosis of thyroid autonomy
In countries with a sufficient iodine supply thyroidal autonomy
will easily be detected by suppressed TSH or a negative TRH-
-test, but not in iodine deficient areas. In these areas quantitative
scintigraphy is indispensable in the diagnosis [3, 9–11].
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In Europe 99m-Tc-pertechnetate (99m-TcO4
-) is the most com-
mon tracer used for thyroid scintigraphy. Compared with iodine
isotopes it has the advantage of daily availability in every nuclear
medicine department, of a shorter physical half-life (6 h) and it
offers preferable energy for scintigraphic imaging (140 keV).
Due to the comparable molecular sizes of 99m-TcO4
–(V = 4.05 ×
× 10-23) and iodine (V = 4.22 × 10-23), pertechnetate is trapped by
the thyroid, but the kinetics differ from iodine isotopes as
99m-TcO4
- is not organified in the gland.
Compared with iodine isotopes 99m-TcO4
- carries a lower radia-
tion burden to the patient, which is due to a shorter effective half-time.
Therefore higher activities can be given, resulting in superior image
quality. The injected standard activity ranges from 37 to 74 MBq.
99m-TcO4
- thyroid uptake (TCTU) increases within the first 15
minutes after intravenous application (influx > efflux), exhibits
a plateau phase between 15 and 30 minutes where in- and efflux
are balanced and decreases again after 30 minutes [4, 12]. The
TCTU (global 99m-Tc-pertechnetate thyroid uptake) is calculated
according to the following formula [12]:
TCTU (%) = 
(counts over thyroid – background counts) ¥ 100
counts of injected activity
In early studies a high correlation between the TCTU and ra-
dioiodine clearance has been recognised [12]. If the TCTU is
measured during the early phase (5–15 min p.i.), the correlation
between thyroidal iodine clearance and TCTU is somewhat stron-
ger than in measurements of the plateau phase, but early deter-
mination of the TCTU requires a more strict time protocol, which
may be difficult to perform under clinical conditions [12, 13].
The clinical value of the TCTU in the diagnosis of thyroidal
autonomy is limited because it represents iodine clearance of both
normal and autonomous tissue. In addition there is a substantial
overlap of the TCTU-values between endemic goitre, euthyroid
and thyrotoxic autonomy and Graves’ disease [10].
As a consequence scintigraphic diagnosis and quantification
of autonomy can only be established if suppressible thyroid tis-
sue has been switched off by TSH-suppression. For this purpose
the TCTUs (global 99m-Tc-pertechnetate thyroid uptake under
suppression) should be determined after long-standing standar-
dised exogenous suppression with thyroid hormones [5, 10]. In
our laboratory 75 µg of thyroxin are given for two weeks, followed
by 150 µg for another two weeks but other regimens may equally
be used with success [5].
In Germany upper normal values of the TCTUs range from
< 1 to < 2% [10]. These differences are due to different regional
iodine supply, different regimens of exogenous suppression and
to methodological aspects. In everyday practice a lot of influen-
ces and disturbing factors have to be considered, too (Table 1).
Clinical implications of TCTUs values beyond the normal will be
discussed in detail in the next chapter.
Indication for definitive treatment
Decisions concerning the definitive treatment of thyroid au-
tonomy should take into account previous episodes of hyperthy-
roidism, objective parameters of risk stratification in euthyroid
patients, as well as concomitant diseases and the probability of
iodine exposure in the future (Table 2).
Patients with autonomy who develop hyperthyroidism carry
a high risk of recurrence, ranging from 55% up to 81% [14]. There
is general agreement that if hyperthyroidism occurs or has oc-
curred in autonomy, definitive treatment is indicated.
In euthyroid patients the spontaneous course of thyroid au-
tonomy should be taken into account in the decision of treating
definitively. In a long-term follow-up in 375 untreated patients with
autonomous solitary thyroid adenoma, the mean incidence of
hyperthyroidism was calculated as 4.1% per year in an iodine
deficiency area, which indicates that all of these patients would
have got hyperthyroid after 25 years [15]. These results show
a similar mean incidence of hyperthyroidism as observed in other
smaller studies carried out in iodine deficiency areas where the
risk of developing hyperthyroidism ranged from 3.7 to < 6% [16,
17].
While advanced age, suppressed TSH, the scintigraphic ap-
pearance of a “decompensated” adenoma and the nodule vol-
ume have no predictive value in the individual prognosis of an
euthyroid patient with thyroidal autonomy [3, 15], the TCTUs may
be a more reliable predictor of hyperthyroidism [5, 18].
In patients with a TCTUs ≥ 3% the risk of spontaneous hyper-
thyroidism is relatively high and thyrotoxicosis was present in 20%
in one study [3]. Therefore these patients should be treated defin-
itively even if they are in a euthyroid state.
Definitive treatment should also be considered in patients with
a TCTUs ranging from 2–3%, especially in the presence of con-
Table 1. Influence and disturbing factors of the TCTU
Disturbing factors
TCTU increases TCTU decreases
Rebound after stopping Intake of
 Levothyroxin  Levothyroxin
 Liothyronin  Liothyronin
 Thyrostatic therapy  Perchlorate
Influences
TCTU increases  TCTU decreases
Thyrotoxicosis  Subacute thyroiditis
lodine deficiency  Chronic atrophic thyroiditis
Primary Hypothyroidism  Secondary hypothyroidism
Lymphocytic Thyroiditis  Renal insufficiency
Table 2. Indications for definitive therapy
Radioiodine therapy or surgery indicated
 Present or earlier hyperthyroidism
 Borderline hyperthyroidism and clinical symptoms
 TCTUs 2–3 or higher in euthyroid patients
 TSH < 0.1 µU/ml in older patients
Indications for preferred surgery
 Larger goitre (> 70 ml)
 Suspected malignancy
 Prompt control of hyperthyroidism
 Iodine contamination
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comitant diseases, as the risk of hyperthyroidism increases con-
tinuously in this group [3, 18]. In patients with TCTUs values smaller
than 2 there is no indication for a definitive therapy, as these pa-
tients will normally not develop hyperthyroidism even if they are
exposed to usual amounts (£ 200 µg) of iodine [5, 19].
Low serum thyrotropin concentrations (< 0.1 µU/ml) have been
found as an independent risk factor for atrial fibrillation in persons
older than 60 years [20]. In our institution, definitive treatment (sur-
gery or radioiodine) is performed in these patients irrespectively
of their individual TCTUs values.
Radioiodine should be the therapy of choice in patients with
autonomy in the absence of a large goitre, in subjects who al-
ready underwent thyroid-surgery and in elderly patients with as-
sociated conditions who carry a high intra- or perioperative risk.
Pregnancy and breast-feeding are absolute contraindications for
radioiodine therapy. Surgery is recommended especially in pa-
tients with large goitres and if malignancy cannot be ruled out. If
prompt control of hyperthyroidism is necessary, especially in thion-
amide-induced agranulocytosis, other severe allergic side-effects
or thionamide/perchlorate resistant thyroid storm, operative treat-
ment should also be preferred [21] (Table 2).
Radiobiology of I-131
I-131 decays with a physical half-life of 8.1 days by β--transi-
tion to Xe-131. 90% of I-131 decays to the 364 keV (g1), 7% to the
637 keV (g2) and 2% to the 723 keV (g3) exited level of Xe-131. All
the nuclei in the 637 keV and 723 keV level decay by g-emission
(g2 + g3) direct to the ground state whilst 7% of the nuclei in the
364 keV level decay via the 80 keV level (g4) and the remainder (g5)
direct to the ground state (Fig. 1).
I-131 is taken up into the thyroid follicular cell by the sodium
iodine symporter on the basolateral membrane of the thyrocyte
[22]. Iodide is then transported through the intracellular space
towards the apical cell surface to follicular lumen. It is suggested
that pendrin, a chloride-iodine transport protein, plays a mayor
role in this process [23]. The next step of iodide handling by the
thyrocyte, the oxidation of iodide into iodine and organification of
iodine into tyrosylresidues of the thyroglobulin molecule, takes
place at the outer (luminal) surface of the apical membrane of the
epithelium.
I-131 is a medium range b–emitter with an average penetra-
tion of 0.44 mm in thyroid tissue. b–particles of the nuclide contrib-
ute to more than 90% of the delivered dose whilst the g-emission
can be used for imaging (Fig. 1).
In normal thyroid tissue an average follicular diameter of 0.05–
–0.5 mm can be expected. In hyperplastic glands this diameter
can be considerably smaller (0.075–0.15 mm), especially in hy-
perfunctioning nodules with a high iodine turnover [24]. If homo-
geneous distribution of I-131 in the colloidal space is assumed,
a homogeneous dose to all cells of the follicle can be expected
(Fig. 1). A considerable dose should also be delivered to the rich
network of blood vessels and the stroma between the follicles.
Thyrocytes are reverting postmitotic cells and therefore rela-
tively radioresistant. Cellular damage of irradiated thyroid tissue,
as seen in early histological specimens after large amounts of
I-131 [25], may be mainly mediated by the more radiosensitive
vasculature [26].
Pre-treatment
In mild hyperthyroidism normally no pre-treatment with an-
tithyroid drugs is recommended [27], while thionamides may
be used to control more severe forms of thyrotoxicosis. As
some of these patients show an elevation of thyroid hormone
levels early after radioiodine treatment, thionamides may be
useful in preventing an aggravation of hyperthyroidism and
thyroid storm. Beta-blockers may prevent clinical aggravation
of symptoms equally effectively as thionamides but euthyroid-
ism is achieved significantly more slowly [28]. As we do not
Figure 1. b– decay of I-131
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know exactly if beta-blockers are equally effective compared
with thionamides in the prevention of thyroid storm we cannot
recommend them as a monotherapy although they may be
useful as an adjunct.
Since the early days of radioiodine therapy it has been sug-
gested that pretreatment with thionamides may reduce the thera-
peutic efficacy of I-131. Some studies found a higher relapse rate
and a decrease in the incidence of post-therapeutic hypothyroid-
ism in patients pre-treated with antithyroid drugs compared with
patients without premedication, especially within the first year af-
ter iodine therapy (overview of the older literature in [29]).
Thionamides, especially if given in high dosages, decrease
radioiodine uptake and alter intrathyroidal iodine kinetics by short-
ening the intrathyroidal half-life of 131I [30, 31]. In addition carbim-
azole, methimazole and propithiouracyl all contain sulfhydryl group-
ings, which may be metabolised within the thyroid gland and form
disulphide bonds with thyroid cell protein, thus preventing cellular
damage following radiation. The radioprotective effect of thiona-
mides may also be due to altered H2O2 production of irradiated
cells or to the shortening of the effective half-life of intrathyroidal
131I by iodine depletion [32].
The results of these early studies remained conflicting as they
may have been biased by patient selection criteria, e.g. treating only
severe hyperthyroidism with thionamides. Moreover other groups
could not confirm these findings even in large collectives [33]. Finally
most of these studies were retrospective and did not use individual
dosimetry, which is commonly used in Central Europe.
Within the last years several prospective studies have been
conducted to evaluate the influence of antithyroid medication on
the efficiency of radioiodine therapy in Graves’ disease [34–36].
Sabri et al. found in a prospective, non-randomised study that
a simultaneous thyrostasis in Graves’ patients was the most im-
portant factor against successful radioiodine therapy [34]. These
findings were later questioned by the results of Andrade et al. and
Körber et al. [35, 36].
Andrade’s prospective and randomised study in a large col-
lective of 813 patients suffers from the fact that the authors did
not correct the I-131-activities given to the individual effective in-
trathyroidal half-life of the isotope in their patients. Therefore their
results cannot be extrapolated to a collective, treated according
to the results of an individual dosimetry [35].
Körber et al. [36] prospectively investigated 141 patients
with Graves’ disease and 418 autonomy-patients, who were
treated by I-131 according to an individual dosimetry. No influ-
ence of a comitant thyroid medication on the patients’ outcome
could be found in the Graves’ group, while thionamides ad-
versely influenced the results of radioiodine treatment in the
autonomy group. In this study the decision criteria of whether
to treat patients with thionamides or not remain unclear and
therefore the results may be biased. In addition it seems that
not all autonomy patients were adequately TSH-suppressed,
which may have negatively influenced the results in this group.
The authors themselves considered that a “steal phenomenon”
of I-131 from autonomous to normal thyroid tissue could ex-
plain the unfavourable results in autonomy patients who were
treated by thionamides.
Although final conclusions about thionamide treatment in au-
tonomy patients suggested for RIT cannot be made from the avail-
able data, we recommend, if clinically feasible, discontinuing thy-
rostasis at least 1 day before beginning the radioiodine test. The
medication should be withheld during the test and within the first
2 days following I-131 treatment and then may be continued if
necessary for several weeks.
A lower incidence of post-therapeutic hypothyroidism has been
recognised if the non-autonomous tissue was sufficiently sup-
pressed during radioiodine treatment [37–40]. Therefore endoge-
nous suppression or suppression by exogenous thyroxin (100–
–150 µg per day over 4–6 weeks) is recommended prior to and
during radioiodine treatment in euthyroid patients and in thiona-
mide treated with measurable TSH-levels.
Dose-estimation
The main rationale for dose estimation is to reduce the pa-
tients’ radiation exposure and to prevent post-therapeutic hypothy-
roidism. Much disagreement exists on this topic. Some groups
have successfully used standard activities without any dosis-cal-
culation [41]. Others modify the fixed dose by giving larger activ-
ities to larger glands [42]. In some centres the activity is calculat-
ed by a fixed activity per gram multiplied with the estimated thy-
roid weight and normalised to the 24 hr uptake value [43, 44]. In
Central Europe the majority of investigators prefer to estimate the
therapeutic activity individually by a radioiodine test. For this pur-
pose Marinelli’s formula is used [45]:
MBq 131I = 
Gy desired × weight of target thyroid tissue × 24.67
maximal uptake(%) × effective half-life
With this approach, determination of the maximal uptake and
estimation of effective half-life of 131I in the thyroid requires up-
take measurements over a couple of days, as the precision of
dose estimation is closely correlated with the number of mea-
surements and the duration of the test [46]. This test should be
performed under identical thyroid medication one or two weeks
prior to radioiodine treatment. Early serial measurements on the
first day are especially important in Graves’ disease with a high
radioiodine turnover, whilst in thyroidal autonomy the maximal
uptake is usually seen after 24 hours or even later [21]. The reli-
ability of this procedure has been questioned, because devia-
tions of up to 100% between the calculated and obtained dose
may theoretically occur [22]. Decrease of iodine uptake values
(< 30%) is usually due to severe iodine contamination, which
cannot be recognised solely by the patients’ history alone in up
to 50% in our experience. If ever possible, determination of uri-
nary iodine excretion should be performed prior to the test and
radioiodine therapy to exclude these patients from actual radio-
iodine treatment.
There has been some controversy if uptake and half-life, as
determined by radioiodine test, could reliably predict uptake and
half-life during therapy [22, 23, 46, 47]. As a consequence, cen-
tres which found a poor correlation between these parameters
rely on individual maximal uptake ratios and combine it with an
empirical half-time. Others who noted a strong correlation under
stable thyroid medication use individual maximal uptake ratios and
individual half-time as determined under test conditions [46]. In
our own experience significant differences between test and ther-
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apeutic dosimetry are rare if antithyroid therapy did not change
between test and radioiodine therapy and occur in < 5% (Meller
et al., unpublished). In these patients additional activity is given to
achieve the estimated dose.
Unifocal autonomy can usually be clearly detected by ultra-
sound, and therefore many investigators use ultrasonographic
volumetry in the determination of the target volume. This method
has some limitations. For example, cystic and other regressive
changes have to be carefully subtracted to avoid overestimation
of the autonomous volume [5]. In addition polyclonal nodules with
sonographic homogeneous and solid appearance may contain
significant amounts of non-autonomous cells.
Some groups tried to determine the autonomous volume in
multifocal autonomy by ultrasonography, too [47]. This appears
to be even more difficult, especially if one considers that in
a multinodular goitre correlation between sonographic and scin-
tigraphic appearance may be difficult or even impossible. In dis-
seminated forms of autonomy ultrasound is generally consid-
ered not to be helpful in the determination of the autonomous
volume.
Agreement exists that a dose of 300–400 Gy should be deliv-
ered to the autonomous tissue in unifocal autonomy (UFA) [27].
As the autonomous volume in multifocal (MFA) or dissemi-
nated autonomy (DISA) cannot be measured by ultrasonogra-
phy with certainty, the sonographic approach to determine the
target volume has been replaced by a so-called “dosimetric
compromise” [37, 48]. For this concept the thyroid gland as
a whole was taken as the target volume and the target dose
was reduced to 150–200 Gy. With this approach, sufficient ther-
apeutic success can only be achieved in patients whose
TCTUs were smaller than 3.2%, thus indicating that higher dos-
es were necessary in a certain thyroid volume if the amount of
autonomous tissue exceeded a critical limit [48]. As a conse-
quence the original concept was modified by adapting the tar-
get dose in MFA/DISA to the TCTUs-values. This modified con-
cept uses the total thyroid volume as a target with stepwise
increasing target doses between 150–300 Gy, dependent on
the pre-therapeutic TCTUs [49].
A more functional approach in the determination of the target
volume was carried out by authors who made an attempt to esti-
mate the “autonomous volume” (AV) directly by a linear correla-
tion of the sonographic volume of unifocal autonomies without
any regressive changes and their corresponding TCTUs values
[5, 50, 51]. In order to estimate the AV independently of its distri-
bution in the thyroid gland this correlation was then extrapolated
to multifocal and disseminated forms of thyroid autonomy. Theo-
retically this method should overcome both the limitations of ultra-
sound volumetry and of a dosimetric compromise. Preliminary data
on this approach indicated success rates of 90%, if the target
dose was beyond 350 Gy [52]. These results could later be con-
firmed by our own group [53].
Results
If elimination of hyperthyroidism is achieved, radioiodine treat-
ment can be considered as successful. Normalisation of serum
TSH and suppressible TCTU have both been proposed as criteria
in the evaluation of post-therapeutic outcome.
Serum TSH > 0.5 excludes autonomous thyroid function with
a probability of 88% in an iodine deficiency area [9]. Therefore
normalisation of this parameter following radioiodine treatment
normally indicates a preferable result.
Persistent suppressed serum TSH after I-131 on the other hand
has a low predictive potential, as it may often be decreased for
a longer time despite therapeutic success [52].
As quantitative scintigraphy has been shown to be more reli-
able in the diagnosis of functional autonomy, determination of the
post-therapeutic TCTUs appears to be the most accurate predic-
tor of whether autonomy has been treated sufficiently or not [52].
In unifocal autonomy, elimination of autonomous tissue is usu-
ally achieved if the target dose exceeds 350 Gy, regardless of
whether the target volume is determined by sonography or calcu-
lated by quantitative scintigraphy [37, 39, 43, 52–54]. If the target
dose is lower, adequate elimination of autonomy cannot usually
be expected [37, 52].
In multifocal and disseminated autonomy, almost all Central
European groups used a dosimetric compromise and took the
whole thyroid volume as a target [37, 48, 49, 54–56]. An estimat-
ed dose of 160 Gy resulted in a high failure rate of 33% in one
study [54]. If the target dose was beyond 200 Gy and the TCTUs
did not exceed a value of 3.2 success rates > 90% were observed.
TCTUs values higher than 3.2 required a higher target dose (300 Gy)
to achieve the same result [55].
As a consequence of these findings Oexle et al. prospec-
tively evaluated the efficiency of a TCTUs-adapted dosimetric
compromise in patients with MFA and DISA [49]. The total thy-
roid was taken as the target volume and the target doses were
increased from 150 Gy to 300 Gy. 150 Gy were used for
a TCTUs of 1.5–2.5%, 200 Gy for a TCTUs of 2.51–3.5%,
250 Gy for a TCTUs of 3.51–4.5%, and 300 Gy for a TCTUs of
> 4.5%. An average success rate of 92% could be observed.
Similar results with this approach were also reported by anoth-
er German group [57].
In the study of Seeger et al. TCTUs values according to Em-
rich’s method were used in the estimation of the autonomous tar-
get volume [50, 52]. Here the target dose was calculated accord-
ing to the formula: autonomous volume (AV) = TCTUs x 5. An
overall success rate of 90% was reported if the target dose was
beyond 350 Gy. Our group used the same method in determining
the target volume in 370 patients [53]. 350–450 Gy to the autono-
mous tissue in our UFA-patients resulted in a high success-rate
of 97%. A lower success rate of 78% was seen in the MFA/DISA
group. Multivariate analysis identified independent factors that ne-
gatively influenced the therapeutic success: a high pre-therapeu-
tic thyroid volume, a high pre-therapeutic TCTUs-value and multi-
focality distribution of the autonomous tissue. These data indi-
cate that the original concept of a merely TCTUs-based RIT is
effective, but has to be corrected in a minority of MFA/DISA pa-
tients with high thyroid volumes (> 100 ml) and/or high TCTUs
(> 3–4%) levels. In these patients a TCTUs-adapted dosimetric
compromise should be used.
Following radioiodine treatment a significant reduction of both
the total and the autonomous thyroidal volume could be observed
[44, 52, 53, 58, 59). RIT was followed by a gradual and dose-
-dependent volume reduction of the hyperfunctioning nodule rang-
ing from 42% to 54% and by a decrease of the non-autonomous
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tissue ranging from 19% to 38%. In multifocal autonomy a de-
crease of the total thyroid volume between 31% and 44% was
observed. While this effect continued up to one year after therapy
in the study of Dederichs et al., maximal reduction of the volume
was seen earlier (3–6 months) by others [53, 44, 59].
Reduction of the extranodular tissue seems to be surprising
and strongly suggests that small amounts of I-131 may be trapped
in the non-autonomous thyroidal tissue, too. Dosimetric calcula-
tions indicate that suppressed tissue may receive as much as 8%
of the total dose, which results in a dose of 3–4 Gy to the non-
autonomous volume [60]. This dose is considerably lower than
the known tolerance dose of 10 Gy that is expected to result in
a 5% incidence of hypothyroidism, but may be high enough to
produce radiation injury to the microvasculature followed by cel-
lular damage [26].
In contrast to Graves’ disease, where high rates of overt hy-
pothyroidism have been accepted as an inevitable part of cure by
many therapists, this condition should be partly avoidable in pa-
tients treated for autonomy. Post-therapeutic hypothyroidism is
dependent on the patients’ preparation as well as on the dose
and the target volume.
Radioiodine therapy in thyroidal autonomy should only be
performed if serum TSH is suppressed because the incidence of
hypothyroidism increases when suppression of extranodular tis-
sue or serum TSH is incomplete [37–40].
The rate of hypothyroidism increases with the target dose. In
one study hypothyroidism increased from 12% to 40% if 400 Gy
instead of 150 Gy were used in multifocal and disseminated au-
tonomies [37].
The incidence of hypothyroidism is relatively low if the ratio
between autonomous volume and perinodular tissue is low [52].
Furthermore, the volume of the autonomous nodule itself is a pre-
dictor for hypothyroidism, as dosimetric estimations indicate that
the dose delivered to the perinodular tissue increases with the
nodule size [60]. Actual patients with large uni- or bifocal autono-
mous nodules have a significantly higher incidence of hypothy-
roidism than patients with smaller nodules [53, 54].
Incidences from Central European centres indicate a risk of
subclinical and overt hypothyroidism ranging from 0 to 56% (aver-
age risk:< 10%) in a follow-up of 0.3 to 15 years (Table 3). Direct
comparisons between the studies are difficult due to heteroge-
neous collectives living under different conditions of iodine sup-
ply, different estimations of the target volume and delivered dose
and a different length of follow-up.
The long-term risk may be even higher, as reported by Holm
et al., who published retrospective data of 4473 Swedish patients
treated with RIT for toxic nodular goitres [33]. 64% of these pa-
tients developed hypothyroidism within 24 years (annual incidence:
2.7%). Holm’s results may indicate that fibrosis is still ongoing
many years after radioiodine treatment.
Early side effects of radioiodine treatment
Early changes in hyperthyroid patients include focal necro-
sis, dilated vessels, oedema and the presence of large multinu-
cleated cells. Within two weeks follicular breakdown and disrup-
tion with presence of extrafollicular colloid are seen. First evi-
dence of fibrosis is noticed at the earliest 3–4 weeks later. Inter-
estingly lymphocytic or granulocytic infiltration could not be ob-
served [25].
Radiation-induced thyroiditis is a clinical entity characterised
by tenderness or pain over the thyroid gland, painful swallowing
and occasional swelling of the thyroid and low grate hyperthermia
over the thyroid region. These clinical findings occur 1–3 days
after radioiodine administration and may be due to the hyperaemia
and oedema described above. Mild discomfort can be treated
with routine analgesics but severe pain requires administration of
glucocorticoids [9]. The incidence of radiation-induced thyroiditis
in radioiodine treatment of benign thyroid diseases is not exactly
known. In early reports it has been noted in 5% of patients treated
with radioiodine [9]. The incidence nowadays seems to be much
lower. Radiation induced thyroiditis was seen in < 2% of our pa-
tients treated for benign thyroid diseases and exclusively if rela-
tively high activities (> 925 MBq) had been given.
Exacerbation of hyperthyroidism: Aggravation of thyrotoxi-
cosis may be due to the release of stored thyroid hormones by
acute radiation damage. Following radioiodine treatment serum
concentrations of thyroid hormones have been observed elevat-
ed by some groups [61, 62], but were found to be unchanged
by others [63, 64].
Kreisig et al. reported the data of early follow-up in 396 pa-
tients. They noted a significant decrease of TT-3 levels immedi-
ately after radioiodine, which was attributed to a hypothetical in-
hibitory effect of I-131. In only 5% of the patients was an increase
of thyroid hormone serum levels observed. No differences in the
serum concentrations could be noted between the patients treat-
ed with thionamides and those without treatment [64]. These re-
sults may indicate that previous studies may have suffered from
bias due to rather small collectives.
Exacerbation of hyperthyroidism and thyroid storm after ad-
ministration of radioiodine has been described in a number of
early case reports. The determination of the incidence of radioio-
dine-induced severe exacerbation of thyrotoxicosis is difficult for
several reasons. In earlier studies only older and multimorbid pa-
tients were included, while in more recent studies younger pa-
tients were selected for radioiodine therapy as well. Furthermore
a great variability of treatment regimens prior to radioiodine exist-
ed between these studies.
In an overview by McDermott et al. the incidence of severe
exacerbation was 0.88 and of thyroid storm 0.34 in 2975 patients
[65]. Severe exacerbation seemed to be neither related to the
activity of radioiodine nor to thyrostatic premedication, although
thionamides had been discontinued in some of the patients prior
to radioiodine treatment. Patients with severe reactions following
radioiodine tended to be older and suffered from severe concom-
itant cardiovascular or cerebrovascular diseases, but the authors
were not able to define a group of patients clearly at risk of deve-
lopment of thyroid storm.
In Kreisig’s study, mentioned above, no severe exacerbation of
thyrotoxicosis could be observed, which indicates that the incidence
of severe reactions should be very low [64]. In our own experience,
thyroid storm did not occur in 1302 patients treated for benign thy-
roid diseases within the last 8 years, although moderate exacerba-
tion of thyrotoxicosis could be found in some patients.
Severe aggravation is not common but it has to be kept in
mind because of its high mortality. It has been questioned if thyro-
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static medication is useful in this respect as it cannot prevent re-
lease of hormones from damaged thyrocytes. Although we lack
data on this topic, thyrostatic pre-treatment and adequate treat-
ment of concomitant diseases should be routinely performed prior
to radioiodine therapy in all patients [27].
Local compression: Theoretically acute swelling and compres-
sion of the trachea and oesophagus may occur after administra-
tion of radioiodine in patients with large goitres, especially follow-
ing high activities. Many authors therefore claim that in these pa-
tients radioiodine should be used with care. Fractional therapy or
single dose therapy with steroid administration is recommended
in patients at risk [66].
We lack data if these side effects have ever been observed
in patients treated with I-131 for benign thyroid diseases. Up to
now only one case report tried to relate an intrathyroidal haem-
orrhage with acute tracheo-oesephageal compression to I-131
treatment 2 months earlier [67]. It remains doubtful if this com-
plication was really due to radioiodine treatment or to spontane-
ous clinical course. In a recent publication in 30 patients suffer-
ing from non-toxic and toxic multinodular goitre, the ultrasono-
graphically determined volume did not increase in the first days
after radioiodine administration [68]. Further prospective stud-
ies concerning early changes of thyroid volume following I-131
seem to be necessary.
Table 3. Results of radioiodine treatment in thyroidal autonomy
Reference Patients Autonomy Target volume Target dose Elimination Hypothyroidism Follow-Up
     (Gy) of autonomy
Berding and Schicha 152 UFA/BFA AV (Sono) 300–400 78–100% 24% 1 yr.
MFA/DISA TV 167 67–89% 9%
Debrand-Passard et al. 126 UFA AV (Sono) 300 95% 36% 0.5–7
MFA AV (Sono) 120-200 80% 21%
DISA TV (Sono) 120-200 98% 56%
Emrich and Reinhardt 38 UFA/MFA/ DISA TV (Sono) 200
TCTU £ 3.2 90% 3% 0.6 yr.
TCTU > 3.2 67% 0%
Guhlmann et al. 230 UFA TV (Sono) 300 93% 5% 1 yr.
MFA TV (Sono)
Heinze et al. 185 UFA 300–400 98% 11% 0.3–8 yr.
Heinze and Bohn 301 UFA AV (Sono) 400 97% 10% < 7 yr.
Hoeschel et al. 130 UFA TV (scintigraphic) 60–150 74% 3.8% 0.6 yr.
MFA
Moser et al. 448 UFA AV (Sono) 400 95% 23% 5.7 yr.
MFA TV (Sono) 150 88% 12% 0.2–5.4 yr.
400 95% 40% 0.2–5.4 yr.
Müller Gärtner et al. 56 UFA AV (Sono) 200 93% 1.7% 2–15 yr.
Reinhard et al. 89 MFA/ DISA TV (Sono)
TCTU £ 3.2 150 95% –
TCTU > 3.2 150 45%
200 50% 1.7% 0.5 yr.
300 90%
Ross et al. UFA AV (Sono) 160 91% 4.5% 0.5–14 yr.
Seeger et al. 131 UFA AV (TCTUs x 5) < 350 57% < 1% 0.9 yr.
MFA /DISA > 350 90% (median)
Oexle et al. 75 MFA /DISA TV (Sono) 150–330 92% 1.5% 0.7 yr.
Meller et al. 370 UFA AV (TCTUs x 5) 350–450 97% 3% 1.5 yr.
MFA /DISA 78%
Dunkelmann et al. 641 UFA TV (Sono) 150–330 91% 3.4% 1.5 yr.
MFA /DISA
UFA — unifocal autonomy, MFA — multifocal autonomy, DISA — disseminated autonomy, AV (Sono) — autonomous volume estimated by sonography, TV — total thyroidal
volume estimated by sonography, AV (TCTUs x 5) — autonomous volume by quantitative scintigraphy
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Late side effects of radioiodine treatment
Histopathological specimens of glands late (4 mth. to 12 yr.)
after radioiodine show evidence of marked fibrosis, follicular dis-
ruption and small irregularly shaped follicles. The vascular lesions
most frequently seen were eosinophilic cuffing and telangiectasia
[25]. Post-radiation fibrosis is progressive over several years. Re-
generation is just focal and irregular. The balance between fibro-
sis and regenerative potential may determine if post-therapeutic
hypothyroidism occurs and cannot be individually predicted .
Patients receiving radioiodine treatment for thyrotoxicosis have
no excess of radiogenic thyroid neoplasms. This is usually as-
cribed to the predominance of substantial cell killing at high dose
rates that are achieved during I-131 therapy [65]. Dobyns et al.
[69] found no excess of thyroid carcinoma in 16000 patients in
a ten-year follow-up and similar results were reported by Holm et
al. [70] and Shore [71]. Unfortunately mean follow-up of these
studies was less than 20 years, but regarding the data from exter-
nal irradiated collectives some excess tumours should already
have been observed within this time.
The cooperative thyrotoxicosis follow-up study group report-
ed no increase in leukaemia in an 8-year follow-up in 19,200 pa-
tients, which was also noted in 1000 patients treated in the Mayo
Clinic [72]. Increased risk of breast cancer, as discussed in thy-
roid cancer patients treated with high activities of I-131, was not
observed in 1005 patients treated for thyrotoxicosis (mean follow-
-up: 15 years).
The data concerning survivors of the atomic bombings of Hi-
roshima and Nagasaki indicate that irradiation at moderated dos-
es did not significantly increase the genetic risk of these subjects
and the following generation [66]. In patients treated with radioio-
dine for hyperthyroidism such studies have not been undertaken,
but it seems unlikely that genetic risk would be observed at go-
nadal doses of the same magnitude as seen in radiological pro-
cedures like intravenous pyelograms and abdominal CT.
Conclusion
Radioiodine therapy for autonomy has been found to be both
effective and safe in thyroid autonomy and without major early or
late side effects. If modern dosimetric and therapeutic approach-
es are used, an overall success rate of 90% or higher can be
achieved. Radioiodine has become the procedure of choice in
autonomy patients with latent or overt hyperthyroidism especially
in the absence of a large goitre, after thyroid surgery and in elder-
ly patients with associated conditions who carry a high intra- or
perioperative risk.
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